Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | PNMT | P11086 | 6/20 | 0.51 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.51 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.51 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TDP2 | O95551 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4429953 | 0.89 | PNMT (0.52) | ALDH1A1SMN1; SMN2PNMTADRA2AADRA2B | |
| SCHEMBL6968655 | 0.84 | ALDH1A1 (0.62) | ALDH1A1SMN1; SMN2PNMTADRA2AADRA2B | |
| SCHEMBL257552 | 0.84 | ALDH1A1 (0.62) | ALDH1A1SMN1; SMN2PNMTADRA2AADRA2B | |
| SCHEMBL10270869 | 0.82 | SIRT2 (0.47) | ALDH1A1SMN1; SMN2PNMTADRA2AADRA2B | |
| SCHEMBL7456470 | 0.81 | PNMT (0.56) | PNMTADRA2AADRA2BADRA2CSIRT2 | |
| SCHEMBL6195263 | 0.79 | SIRT2 (0.45) | PNMTADRA2AADRA2BADRA2CSIRT2 | |
| SCHEMBL27799204 | 0.79 | SIRT2 (0.45) | ALDH1A1SMN1; SMN2PNMTADRA2AADRA2B | |
| SCHEMBL6197463 | 0.78 | PNMT (0.54) | PNMTADRA2AADRA2BADRA2CSIRT2 | |
| SCHEMBL2776754 | 0.76 | PNMT (0.42) | ALDH1A1SMN1; SMN2PNMTADRA2AADRA2B | |
| SCHEMBL28431711 | 0.74 | SIRT2 (0.43) | ALDH1A1SMN1; SMN2PNMTADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210678-A1 | Tricyclic androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED | 2010-08-19 | — | — | US | disclosed |
| US-7727980-B2 | Tricyclic androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2010-06-01 | — | — | US | disclosed |
| EP-0198264-A2 | Carbamoyl imidazoles | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1986-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210678-A1 | Tricyclic androgen receptor modulator compounds and methods | AR, NR5A1, ESRRA | ALDH1A1 1403/4885SMN1; SMN2 4879/4885PNMT 769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.